Dear members of the ELN,

This Saturday, the 2012 ASH Annual Meeting and Exposition starts in Atlanta. In this issue we prepared some information on ELN meetings that take place in the course of the congress and other interesting news connected to ASH and - of course - to the ELN.

We would like to take the opportunity to thank all members for their support in 2012 and send you our very best wishes for the forthcoming holidays and for a good start to the new year.

Kind regards,
European Leukemia Information Center - ELIC

ELN Breakfast Meeting and WP meetings at the ASH 2012
On Sunday December 9th the ELN breakfast meeting takes place at Hilton Atlanta – Grand Ballroom East. The agenda of this meeting as well as of different work package meetings is now available on the website. 

The ELN website is in compliance with the HONcode
As in previous years the website of the European LeukemiaNet successfully passed the quality check of the Health On the Net Foundation (HON). The HONcode certificate is awarded to websites that coincide with the 8 principles of the HONcode of Conduct (authoritative, complementarity, privacy, attribution, justifiability, transparency, financial disclosure and advertising policy). For detailed information on this quality label please click on the HONcode logo on the ELN homepage.

Renaming of WP13
The ELN work package 13 “Gene profiling” was renamed. Due to new methods and technologies WP13 will in future be referred to as “Next generation sequencing”. For more information on WP13 please have a look at Next generation sequencing.

ASH: Summary of oral presentations
In order to provide all network members with information on “advances in the field” ELIC is aiming to publish summaries on the most important ASH abstracts of oral presentations on the therapy/treatment of leukemia in cooperation with the respective WP leaders. These overviews will soon be available on the website and will also be published in the upcoming Information Letter.

Publications from the Network (selected)


### New trials in the ELTR

**HCT vs CT**  Randomized Phase III Study Comparing Conventional Chemotherapy to Low Dose Total Body Irradiation-Based Conditioning and HCT From Related and Unrelated Donors as Consolidation Therapy for Older Patients With AML in 1st Complete Remission

**B1931022**  An Open-Label, Randomized Phase 3 Study Of Inotuzumab Ozogamicin Compared To A Defined Investigator’s Choice In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)

---

**European Leukemia Information Center - ELIC**  
Dr. Nicola Gökbüget, Dr. Sina Hehn  
Johann Wolfgang Goethe University Hospital | Department of Medicine II  
Theodor-Stern-Kai 7 | 60590 Frankfurt am Main, Germany  
++49 (0)69 6301 6365 | **ELIC@em.uni-frankfurt.de** | [www.leukemia-net.org](http://www.leukemia-net.org)